TITLE

Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis

AUTHOR(S)
Breyer-Pfaff, U; Schmezer, A; Maier, U; Brinkmann, A; Schumm, F
PUB. DATE
June 1990
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Jun1990, Vol. 53 Issue 6, p502
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
No abstract available.
ACCESSION #
66099850

 

Related Articles

  • pyridostigmine.  // Royal Society of Medicine: Medicines;2002, p462 

    This article presents information on pyridostigmine, an anticholinesterase drug which enhances the effects of the neurotransmitter acetylcholine. It is more commonly used to treat the neuromuscular transmission disorder myasthenia gravis.

  • Bromide Intoxication Secondary to Pyridostigmine Bromide Therapy. Rothenberg, David M.; Berns, Arnold S.; Barkin, Robert; Glantz, Russell H. // JAMA: Journal of the American Medical Association;2/23/90, Vol. 263 Issue 8, p1121 

    Presents a case of bromide intoxication detected initially by a negative anion gap and later confirmed by direct measurement of the serum bromide level in a patient with myasthenia gravis being treated with high dose pyridostigmine bromide. Case history; Laboratory values for a patient...

  • Survey Shows New Mayo Clinic Treatment for Intractable Low Blood Pressure Works Well to Control Dizziness, Fainting; Has Few Side Effects.  // Ascribe Newswire: Medicine;4/29/2004, p103 

    Patients are generally pleased with a new Mayo Clinic drug treatment for a common form of impaired nerve transmission that causes dizziness and fainting when patients change position from lying down to standing up, and most want to continue using it. This finding on patients' satisfaction of the...

  • Survey Shows New Mayo Clinic Treatment for Intractable Low Blood Pressure Works Well to Control Dizziness, Fainting; Has Few Side Effects.  // Ascribe Newswire: Medicine;5/3/2004, p93 

    Patients are generally pleased with a new Mayo Clinic drug treatment for a common form of impaired nerve transmission that causes dizziness and fainting when patients change position from lying down to standing up, and most want to continue using it. This finding on patients' satisfaction of the...

  • Myasthenia Gravis. Engel, W. King; Festoff, Barry W.; Patten, Bernard M.; Swerdlow, Michael L.; Newball, Harold H.; Thompson, Mary D. // Annals of Internal Medicine;Aug74, Vol. 81 Issue 2, p225 

    Focuses on attributes of the neuromuscular disease myasthenia gravis to dysfunction at the neuromuscular junction. Cause of the weakness of myasthenia gravis; Ultraphysiology of neuromuscular transmission; Characteristic feature of the myasthenic state; Therapeutic effect of alternate-day...

  • Mestinon.  // Royal Society of Medicine: Medicines;2002, p356 

    The article presents information on mestinon, a proprietary, prescription-only preparation of the anticholinesterase and parasympathomimetic pyridostigmine. This drug can be used to treat myasthenia gravis. It is available as tablets.

  • Myasthenia Gravis in an Exotic Shorthair Cat. Macedo, Aline Schafrum; Silva, Renato Barbosa; Fett, Rochana Rodrigues; Minto, Bruno Watanabe // Acta Scientiae Veterinariae;2015 Supplement 1, Vol. 43, p1 

    Background: Myasthenia gravis is a neuromuscular transmission disorder resulting from the deficiency or functional disturbance of the acetylcholine receptors at the neuromuscular junction with consequent impairment of action potential transmission from nerve to muscle and it can be either...

  • Clinical diagnosis and different management of acquired myasthenia gravis in a Pekingese. Shirani, Darioush; Ardestani, Bijan; Ardestani, Shadi; Mohyedini, Shahabedin // Comparative Clinical Pathology;Jun2011, Vol. 20 Issue 3, p285 

    Myasthenia gravis is a neuromuscular transmission disorder that occurs in two forms, acquired and congenital. Acquired myasthenia gravis is probably the most common neuromuscular disorder in dogs that can be diagnosed and treated. This report focuses on the clinical diagnosis and treatment of...

  • Edrophonium/pyridostigmine.  // Reactions Weekly;12/17/2011, Issue 1382, p18 

    The article describes the case of a 27-year-old woman, with autoimmune myasthenia gravis, who developed hypersalivation and fasciculations during treatment with edrophonium and pyridostigmine.

  • Pyridostigmine.  // Reactions Weekly;9/11/2010, Issue 1318, p39 

    The article describes the case of a 40-year-old woman who developed dystonic blepharospasm while under pyridostigmine treatment regimen for myasthenia gravis.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics